Natural Alternatives International, Inc. — Form 10-Q summary
Period: The filing covers the quarter and nine months ended March 31, 2014, the company’s fiscal third quarter of 2014. This differs from the “2013 Q3” period in the request metadata. Amounts are in U.S. dollars; financial statement amounts are in thousands unless stated otherwise.
Business context and reporting period
NAI manufactures nutritional supplements for customers, licenses patents and trademarks related mainly to beta-alanine sold as CarnoSyn, and sells branded products, primarily Pathway to Healing. The interim financial statements are unaudited. NAI said quarterly results are not necessarily indicative of full-year results.
Financial performance and liquidity
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Net sales | 2014: $19.127 million; 2013: $15.835 million | 2014: $52.757 million; 2013: $45.981 million |
| Gross profit / margin | $3.442 million / 18.0%; prior year 18.1% | $8.701 million / 16.5%; prior year 18.8% |
| Operating income | $1.168 million; prior year $569,000 | $1.522 million; prior year $1.325 million |
| Net income / diluted EPS | $622,000 / $0.09; prior year $178,000 / $0.03 | $904,000 / $0.13; prior year $977,000 / $0.14 |
| Operating cash flow | Nine months: $571,000, versus $2.067 million in the prior-year period |
- At March 31, 2014, cash and cash equivalents were $15.217 million, down from $16.697 million at June 30, 2013. Current assets were $38.636 million and current liabilities $8.183 million.
- Inventory rose to $14.367 million from $10.035 million at June 30, 2013; the increase used $4.332 million of cash during the nine-month period. Management attributed the build to higher demand and the timing of shipments and receipts.
- Capital expenditures were $2.198 million for the nine months, compared with $1.379 million in the prior-year period. NAI reported no consolidated debt, no borrowings on its credit lines, and $5.6 million available under credit facilities. It was in compliance with credit covenants.
Material changes versus the prior comparable period
- Quarterly sales rose 21% and nine-month sales rose 15%. Private-label contract manufacturing sales increased 22% in the quarter and 15% for nine months, supported by new products and customers and higher volumes of existing products. Nine-month results were partly offset by lower prices on some high-volume products and unfavorable euro exchange rates.
- CarnoSyn patent and trademark licensing sales increased 13% in the quarter and 19% for nine months. Branded product sales declined 8% and 11%, respectively, due mainly to softer Pathway to Healing sales.
- Nine-month gross margin fell 2.3 percentage points, primarily because of lower average prices, less favorable product mix, and lower euro exchange rates in contract manufacturing. Quarterly margin was nearly unchanged.
- Quarterly net income increased substantially, while nine-month net income declined 8%, reflecting higher income tax expense. Nine-month operating cash flow also fell, in part because inventory consumed more cash and receivables provided less cash than in the prior-year period.
- Revenue concentration eased: the two largest private-label manufacturing customers represented 53% of that segment’s sales for the first nine months, compared with 70% a year earlier. Management expected the percentage to remain materially consistent for the remainder of fiscal 2014.
Outlook, commentary, risks and unusual items
- NAI gave no specific sales or earnings guidance. Management said available cash, expected operating cash flows, and credit availability should be sufficient for working capital and capital expenditures through at least the next 12 months.
- Abbott terminated its beta-alanine license and supply agreement effective November 27, 2013, citing additional time and cost needed to bring its anticipated product to market. NAI said no further license fees would be paid under that agreement.
- NAI incurred approximately $1.7 million of litigation and patent-compliance expenses in the first nine months of fiscal 2014, versus $1.8 million in the prior-year period. Patent litigation remains pending; the USPTO rejected claims of NAI’s ’381 patent and NAI appealed. A re-examination of the ’422 patent was also underway. Adverse patent rulings could materially affect the business.
- NAI is named in multiple product-liability lawsuits concerning products it said it did not formulate, manufacture, distribute, or sell. The company reported seeking indemnification in certain cases and relying on insurance-appointed defense counsel. Outcomes and potential costs remain uncertain.
- The quarter’s effective tax rate was 40.9%; the nine-month rate was 37.2%. Discrete state-tax adjustments included a $193,000 valuation allowance against a California net-operating-loss deferred tax asset. Unrecognized tax benefits were approximately $88,000.
- Customer and supplier concentration, availability of beta-alanine and other raw materials, customer order timing, foreign exchange movements, patent protection, and product returns or recalls are identified risks. NAI reported no material off-balance-sheet arrangements and said disclosure controls were effective at March 31, 2014.
Important facts for investors to verify
- Confirm the period intended: this filing is fiscal Q3 2014, not 2013 Q3.
- Track whether contract-manufacturing growth continues while customer concentration remains high, and whether the margin decline reverses.
- Assess the effect of Abbott’s termination on future licensing revenue and the sustainability of CarnoSyn royalties.
- Monitor inventory levels, operating cash generation, capital spending, and the assumptions behind management’s 12-month liquidity assessment.
- Follow patent re-examinations and litigation, product-liability claims, and tax matters for developments that could change costs or risk exposure.